TimesSquare Capital Management LLC Has $8.06 Million Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

TimesSquare Capital Management LLC decreased its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 6.4% during the 1st quarter, Holdings Channel reports. The institutional investor owned 397,200 shares of the company’s stock after selling 27,200 shares during the period. TimesSquare Capital Management LLC’s holdings in Taysha Gene Therapies were worth $8,063,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of TSHA. Citigroup Inc. acquired a new position in Taysha Gene Therapies during the 4th quarter worth about $43,000. Strs Ohio acquired a new position in Taysha Gene Therapies during the 4th quarter worth about $55,000. New York State Common Retirement Fund acquired a new position in Taysha Gene Therapies during the 4th quarter worth about $130,000. American International Group Inc. acquired a new position in Taysha Gene Therapies during the 4th quarter worth about $134,000. Finally, Wells Fargo & Company MN acquired a new position in Taysha Gene Therapies during the 4th quarter worth about $330,000. Institutional investors and hedge funds own 44.90% of the company’s stock.

TSHA has been the topic of several research reports. Cantor Fitzgerald initiated coverage on shares of Taysha Gene Therapies in a research report on Wednesday, May 19th. They set an “overweight” rating and a $44.00 price target on the stock. William Blair began coverage on Taysha Gene Therapies in a report on Tuesday, February 23rd. They set an “outperform” rating and a $46.00 price objective for the company. Zacks Investment Research cut Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Tuesday, March 9th. Morgan Stanley boosted their price objective on Taysha Gene Therapies from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Tuesday, April 13th. Finally, JMP Securities began coverage on Taysha Gene Therapies in a report on Tuesday. They set an “outperform” rating and a $40.00 price objective for the company. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $42.06.

Shares of TSHA stock opened at $24.60 on Friday. The company has a market cap of $932.76 million and a PE ratio of -7.24. The company has a 50-day moving average of $22.53. Taysha Gene Therapies, Inc. has a one year low of $18.16 and a one year high of $33.35.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Tuesday, May 11th. The company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.33). On average, analysts forecast that Taysha Gene Therapies, Inc. will post -3.37 EPS for the current fiscal year.

In related news, Director Paul B. Manning acquired 12,000 shares of the business’s stock in a transaction dated Friday, May 14th. The stock was bought at an average price of $20.98 per share, with a total value of $251,760.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Sean P. Nolan acquired 1,170 shares of the business’s stock in a transaction dated Thursday, May 20th. The stock was bought at an average cost of $22.35 per share, with a total value of $26,149.50. Following the acquisition, the director now owns 1,170 shares in the company, valued at approximately $26,149.50. The disclosure for this purchase can be found here. Corporate insiders own 41.80% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome.

Featured Article: What is a Stop Order?

Want to see what other hedge funds are holding TSHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. (NASDAQ:TSHA).

Institutional Ownership by Quarter for Taysha Gene Therapies (NASDAQ:TSHA)

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.